Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McMaster University

$112,076.00

Real world Comparative Effectiveness and Safety of Dabigatran versus Warfarin

FY 2012-13

Summary
Dabigatran is the first in a series of new anticoagulants approved for atrial fibrillation (AF), which is the most common chronic heart rhythm problem in Canada and a common cause of stroke. Warfarin has been the standard anticoagulant for more than 50 years, with more than 5 million prescriptions written in 2010 in Canada. It is one of the most effective medications in chronic use. Dabigatran was approved for AF in 2010, and its use has increased rapidly amidst huge controversy over its relative effectiveness (stroke reduction) and safety (bleeding, heart attacks, lack of antidote, stopping) compared to warfarin. Dabigatran was the most common drug cause of severe or fatal injury reported to the United States FDA in 2011. Public drug plans in Canada, which provide for more than 95% of Canadian seniors, have indicated a strong interest in further evidence as to whether dabigatran is really as good or better than warfarin in usual clinical practice, and which patients will do better on which drug. We plan to compare the safety and effectiveness of these drugs using British Columbia health databases on prescription drugs, hospitalizations, medical services, and deaths with a novel linkage to laboratory test results. In a study group of over 40,000 new users of dabigatran or warfarin, followed for at least 12 months, we will compare the frequency of strokes, dangerous blood clots, heart attacks, hospitalization for bleeding, and deaths. Our unique, secure access to patient-specific laboratory results, allows us unprecedented ability to explain which patients will do better on dabigatran and who will do better on warfarin, using key tests of kidney, liver and blood function. Our team includes experts on anticoagulant drugs and their use by patients, plus experts on the British Columbia databases and on statistical methods for studies of drug effectiveness and safety.
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
266155
Name
Holbrook Anne M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Services Evaluation & Interventions Research 2
Projecttitle
Real world Comparative Effectiveness and Safety of Dabigatran versus Warfarin
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$112,076
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Anticoagulants; Community Laboratory Data; Comparative Effectiveness; Dabigatran; Health Information Privacy; Linked Healthcare Databases; Propensity Score; Retrospective Cohort Design; Warfarin
Abstract
Dabigatran is the first in a series of new anticoagulants approved for atrial fibrillation (AF), which is the most common chronic heart rhythm problem in Canada and a common cause of stroke. Warfarin has been the standard anticoagulant for more than 50 years, with more than 5 million prescriptions written in 2010 in Canada. It is one of the most effective medications in chronic use. Dabigatran was approved for AF in 2010, and its use has increased rapidly amidst huge controversy over its relative effectiveness (stroke reduction) and safety (bleeding, heart attacks, lack of antidote, stopping) compared to warfarin. Dabigatran was the most common drug cause of severe or fatal injury reported to the United States FDA in 2011. Public drug plans in Canada, which provide for more than 95% of Canadian seniors, have indicated a strong interest in further evidence as to whether dabigatran is really as good or better than warfarin in usual clinical practice, and which patients will do better on which drug. We plan to compare the safety and effectiveness of these drugs using British Columbia health databases on prescription drugs, hospitalizations, medical services, and deaths with a novel linkage to laboratory test results. In a study group of over 40,000 new users of dabigatran or warfarin, followed for at least 12 months, we will compare the frequency of strokes, dangerous blood clots, heart attacks, hospitalization for bleeding, and deaths. Our unique, secure access to patient-specific laboratory results, allows us unprecedented ability to explain which patients will do better on dabigatran and who will do better on warfarin, using key tests of kidney, liver and blood function. Our team includes experts on anticoagulant drugs and their use by patients, plus experts on the British Columbia databases and on statistical methods for studies of drug effectiveness and safety.
Competitiondate
201209
Approvedterm2
1 yr 6 mths
Pinamesdelim
Holbrook, Anne M
Approvedterm
1 an 6 mois
Cihrcontribution2
~ $112,076~ $0~
McMaster University - $112,076 Grant (2012-13) | Canada Spends